Patents by Inventor David Moore Glover

David Moore Glover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITING GENE EXPRESSION WITH dsRNA
    Publication number: 20180355352
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: July 26, 2017
    Publication date: December 13, 2018
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • INHIBITING GENE EXPRESSION WITH dsRNA
    Publication number: 20170096667
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: October 14, 2016
    Publication date: April 6, 2017
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • INHIBITING GENE EXPRESSION WITH dsRNA
    Publication number: 20150047064
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • Inhibiting Gene Expression with dsRNA
    Publication number: 20080242628
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: October 31, 2007
    Publication date: October 2, 2008
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • Inhibiting Gene Expression with dsRNA
    Publication number: 20080221054
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: October 31, 2007
    Publication date: September 11, 2008
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • Mus101 and homologue thereof
    Publication number: 20030170655
    Abstract: Plynucleotides encoding a novel Drosophila gene product designated mus101 and homologues thereof as well as mus101 polypeptides are provided. Polynucleotide probes derived from the nucleotide sequence of mus101 and antibodies that bind to mus101 protein are also provided as well as assays for identifying substances that regulate mus101 function.
    Type: Application
    Filed: November 13, 2002
    Publication date: September 11, 2003
    Inventors: David Moore Glover, Rochele Yamamoto, Daryl Henderson
  • Cell cycle progression proteins
    Publication number: 20030152945
    Abstract: Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.
    Type: Application
    Filed: May 30, 2002
    Publication date: August 14, 2003
    Applicant: Cyclacel Limited
    Inventors: Peter Deak, David Moore Glover, Carol Midgley
  • Inhibiting gene expression with dsRNA
    Publication number: 20030027783
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: May 17, 2002
    Publication date: February 6, 2003
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • Identification of the P21WaF1-PCNA interaction site and therapeutic applications thereof
    Patent number: 6242201
    Abstract: Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: June 5, 2001
    Assignee: Cyclacel Limited
    Inventors: David Philip Lane, Lynne Suzanne Cox, Emma Warbrick, David Moore Glover